.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Prof. Dr. Andrew Hemphill

Bern / CH

Institute of Parasitology, University of Bern

Chair

15/03/2023
14:45 – 16:15
Scientific Session
Drug Development/ Resistance
HS II (GF)

Speaker

15/03/2023
15:15 – 15:30 10 Min. 5 Min.
Talk
A14
Differential affinity chromatography coupled to mass spectrometry: a 3R-relevant tool to identify common binding proteins of a broad-range antimicrobial peptide and potentially other compounds active against Toxoplasma gondii
Drug Development/Target Identification, Parasite-Host Interaction
17/03/2023
14:30 – 14:45 10 Min. 5 Min.
Talk
A139
Proteomic characterization of Toxoplasma gondii ME49 derived strains resistant to the artemisinin derivatives artemiside and artemisone implies potential mode of action independent of ROS formation
Drug Development/Target Identification, Drug Resistance

Further involvements

15/03/2023
15:15 – 15:30 10 Min. 5 Min.
Talk
A14
Differential affinity chromatography coupled to mass spectrometry: a 3R-relevant tool to identify common binding proteins of a broad-range antimicrobial peptide and potentially other compounds active against Toxoplasma gondii
Drug Development/Target Identification, Parasite-Host Interaction
16/03/2023
11:00 – 11:15 10 Min. 5 Min.
Talk
A43
A comparative proteomic analysis of Toxoplasma gondii RH wild-type and four SRS29B (SAG1) knock-out clones to understand the impact of sag1 disruption on the gene expression profile during the lytic cycle in vitro
Molecular Parasitology
17/03/2023
13:30 – 13:45 10 Min. 5 Min.
Talk
A129
Objective in vitro drug testing for Echinococcus granulosus
Drug Development/Target Identification, One Health/NTD/Zoonoses
17/03/2023
14:30 – 14:45 10 Min. 5 Min.
Talk
A139
Proteomic characterization of Toxoplasma gondii ME49 derived strains resistant to the artemisinin derivatives artemiside and artemisone implies potential mode of action independent of ROS formation
Drug Development/Target Identification, Drug Resistance